Literature DB >> 18752126

WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis.

C J R Stewart1, B A Brennan, T Chan, J Netreba.   

Abstract

AIMS: To determine how frequently endometrioid ovarian carcinomas (EOC) express WT1 protein, and to correlate the results with the presence of endometriosis and p53 immunoreactivity.
METHODS: Forty-one grade 1-2 EOC were stained immunohistochemically for WT1 and p53 proteins. Twenty-one tumours were associated with endometriosis and 20 cases lacked such an association. WT1 expression in the tumour cell nuclei and/or cytoplasm was recorded. Nuclear p53 staining was assessed as diffuse (>50% cells positive), focal, or negative.
RESULTS: Four of the 20 (20%) tumours in the endometriosis negative group showed nuclear WT1 staining, while none of the endometriosis-associated EOC was positive (p < 0.05). Two of the immunoreactive cases exhibited sertoliform/sex cord-like patterns. Focal cytoplasmic WT1 labelling was present in seven EOC, three of which showed sertoliform, spindle cell or corded and hyaline patterns. There was no correlation between WT1 expression and p53 immunoreactivity.
CONCLUSIONS: Nuclear WT1 expression is present in a minority of EOC and this should be considered if immunohistochemistry is used as an adjunct in sub-typing ovarian carcinomas. The negative correlation of WT1 staining with endometriosis supports the possibility that some EOC, including unusual histological variants, arise from the ovarian surface epithelium. Further studies of EOC should document any association with endometriosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752126     DOI: 10.1080/00313020802320697

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  6 in total

1.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

Review 2.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

Review 3.  Adenomyosis as a Risk Factor for Myometrial or Endometrial Neoplasms-Review.

Authors:  Maria Szubert; Edward Kozirog; Jacek Wilczynski
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

4.  Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Authors:  Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook
Journal:  Int J Gynecol Pathol       Date:  2019-07       Impact factor: 2.762

5.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.

Authors:  Martin Köbel; Kurosh Rahimi; Peter F Rambau; Christopher Naugler; Cécile Le Page; Liliane Meunier; Manon de Ladurantaye; Sandra Lee; Samuel Leung; Ellen L Goode; Susan J Ramus; Joseph W Carlson; Xiaodong Li; Carol A Ewanowich; Linda E Kelemen; Barbara Vanderhyden; Diane Provencher; David Huntsman; Cheng-Han Lee; C Blake Gilks; Anne-Marie Mes Masson
Journal:  Int J Gynecol Pathol       Date:  2016-09       Impact factor: 2.762

6.  Is there a relationship in-between ovarian endometriosis and ovarian cancer? Immunohistochemical profile of four cases with coexisting ovarian endometriosis and cancer.

Authors:  Roxana Cleopatra Penciu; Iulia Postolache; Liliana Steriu; Silvia Izvoranu; Andrei Adrian Tica; Iulia Diana Mocanu; Vasile Sârbu; Mariana Deacu; Irina Tica; Gabriela Izabela Bălţătescu; Oana Sorina Tica; Vlad Iustin Tica
Journal:  Rom J Morphol Embryol       Date:  2020       Impact factor: 1.033

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.